Portal Hypertension: Comprehensive Overview
Definition and Pathophysiology
Portal hypertension is a pathological increase in portal pressure (>5 mmHg) characterized by formation of portal-systemic collaterals that bypass the liver, with clinically significant portal hypertension (CSPH) defined as hepatic venous pressure gradient (HVPG) ≥10 mmHg 1.
Portal hypertension arises from two key mechanisms:
- Fixed structural changes: Fibrosis, angiogenesis, nodule formation, and vascular occlusion distorting liver microcirculation
- Dynamic changes: Increased vascular tone from imbalanced vasodilators/vasoconstrictors affecting hepatic stellate cells and myofibroblasts 1
Anatomic Classification
Portal hypertension must be characterized by anatomic location of impaired blood flow 1:
- Prehepatic: Splenic, mesenteric, or extrahepatic portal vein involvement
- Intrahepatic: Parenchymal liver diseases (cirrhosis is the most common cause in Western countries)
- Posthepatic: Hepatic venous outflow obstruction
The hemodynamic abnormality involves both increased intrahepatic resistance and splanchnic vasodilation (primarily from increased nitric oxide production), which increases portal blood flow and maintains the hypertensive state 2.
Diagnosis and Severity Assessment
Invasive Gold Standard
HVPG measurement via hepatic vein catheterization remains the gold standard for diagnosing and monitoring portal hypertension 2. Key thresholds:
- Normal HVPG: 3-5 mmHg
- Portal hypertension: >5 mmHg
- CSPH: ≥10 mmHg (threshold where complications become likely)
- High bleeding risk: >12 mmHg (protective threshold for variceal hemorrhage prevention)
- Increased mortality risk: >16 mmHg
- Failure to control bleeding/early rebleeding: ≥20 mmHg 2
Critical caveat: HVPG only measures sinusoidal pressure and provides no useful data in prehepatic or presinusoidal portal hypertension 2.
Non-Invasive Diagnostic Approaches
Recent advances emphasize non-invasive methods for diagnosis and monitoring 3, 4, 5:
- Liver stiffness measurement (LSM) via elastography
- Spleen stiffness measurement (SSM): Shows superior linear correlation with HVPG at higher pressure ranges 6
- Serum biomarkers: FIB-4 index for initial screening; VITRO score (von Willebrand factor-to-platelet ratio) reduces diagnostic grey zones 6
- Imaging: Doppler ultrasound as first-line, CT for confirmation and extension assessment 7
- Magnetic resonance elastography (MRE): Highest diagnostic reliability in obese populations 6
Clinical Indicators of Portal Hypertension
Diagnosis can be confirmed by 7:
- Splenomegaly/hypersplenism (must be accompanied by additional signs)
- Esophageal varices on endoscopy
- Ascites (non-malignant)
- Minimally increased HVPG
- Portosystemic collaterals on imaging
Complications and Prognostic Impact
Ascites
Ascites is the most common complication, developing in nearly 60% of patients within a decade of compensated cirrhosis diagnosis 1. This marks decompensation and dramatically worsens prognosis:
- Compensated cirrhosis: 80% 5-year survival
- After ascites development: 50% 5-year survival without transplantation 1
Ascites predisposes to:
- Dilutional hyponatremia
- Refractory ascites
- Hepatorenal syndrome (HRS)
- Spontaneous bacterial peritonitis
When refractory to medical treatment, 1-year mortality ranges from 20-50% 1.
Hepatorenal Syndrome
HRS is a frequent and grave complication triggered by arterial vasodilation in splanchnic circulation 1:
- Type 1 HRS: Progressive, severe, rapid decline in renal function
- Type 2 HRS: More constant renal dysfunction, commonly associated with refractory ascites 1
Management Strategies
Medical Management
Non-selective beta-blockers (NSBBs) are the cornerstone of medical therapy, acting through both β-1 (decreased cardiac output) and β-2 (splanchnic vasoconstriction) blockade 2. The β-2 blocking effect is more important than heart rate reduction for decreasing portal pressure 2.
Available NSBBs:
- Propranolol
- Nadolol
- Carvedilol: NSBB with anti-α1 adrenergic activity, providing both decreased portal flow and intrahepatic vasodilation 2
NSBBs reduce both variceal hemorrhage risk and hepatic decompensation 8.
Acute Variceal Bleeding Management
For acute variceal hemorrhage, combine vasoactive drugs (terlipressin, somatostatin, or octreotide) with early endoscopic therapy 8. Endoscopic variceal ligation (EVL) involves placing rubber bands around varices 2.
TIPSS (Transjugular Intrahepatic Portosystemic Stent-Shunt)
TIPSS is a non-surgical intervention placing a metal stent through the jugular vein into the liver, performed under general anesthesia or deep sedation, taking 90-120 minutes 9.
Strong Indications for TIPSS 9:
- Acute variceal bleeding unresponsive to endoscopy and medical therapy (patients with very severe liver disease unlikely to benefit)
- Secondary prevention of variceal rebleeding after failure of standard endoscopic and medical therapies
- Refractory ascites or hepatic hydrothorax (effective for fluid reduction, though survival benefit unclear)
- Budd-Chiari syndrome in specialist centers with transplantation capability
- Portal vein thrombosis in selected patients at high-volume centers
Pre-TIPSS Preparation 9:
- Cross-sectional imaging of liver and vessels
- Liver and kidney function tests
- Coagulation studies
- Cardiac function assessment
- Nutritional evaluation
- Hepatic encephalopathy risk assessment
TIPSS Technical Specifications 9:
- Use PTFE-covered stents (better patency than bare stents)
- Target portal pressure gradient <12 mmHg or ≥20% reduction from baseline for variceal bleeding
- Measure gradient between portal pressure and IVC pre- and post-deployment
- Prophylactic antibiotics only for: variceal bleeding, complex procedures, or previous biliary instrumentation
- Correct coagulopathy based on thromboelastography (INR unreliable in liver disease)
- Consider platelet transfusion if count <50×10⁵/L 9
TIPSS Complications 9:
Acute complications (<5% of patients):
- Bleeding, infection, heart failure, liver failure, kidney failure, fever, vascular/bile duct damage
Long-term complications:
- Hepatic encephalopathy (HE): Affects one-third of patients; most respond to medical therapy, but some require TIPSS closure 9
Post-TIPSS Surveillance 9:
- Doppler ultrasound 1 week post-procedure in prothrombotic conditions or suspected dysfunction
- Routine Doppler at 6-12 month intervals (6-monthly if HCC surveillance needed)
- Prothrombotic conditions (e.g., Budd-Chiari) require careful follow-up with consideration for venography
- No routine venography indicated in other patients
Surveillance and Prevention
Surveillance for gastroesophageal varices is recommended when clinical, ultrasonographic, elastography, or platelet count data suggest portal hypertension 10:
- No varices at index endoscopy: Repeat in 2 years
- Small varices at index endoscopy: Repeat in 1 year
NSBBs or endoscopic treatment are recommended for primary prophylaxis to reduce bleeding risk and mortality 10.
Special Populations
Idiopathic Non-Cirrhotic Portal Hypertension (INCPH)
Diagnosis requires 7:
- Clinical signs of portal hypertension (splenomegaly/hypersplenism, varices, ascites, collaterals)
- Exclusion of cirrhosis on biopsy
- Exclusion of chronic liver disease causing cirrhosis
- Exclusion of other non-cirrhotic portal hypertension causes
- Patent portal and hepatic veins
Manage portal hypertension according to cirrhosis guidelines once prophylaxis for bleeding implemented 7. Consider permanent anticoagulation in strong prothrombotic conditions or history suggesting intestinal ischemia; long-term anticoagulation indicated with underlying myeloproliferative neoplasm 7.
Extrahepatic Portal Vein Obstruction
- Screen patients with myeloproliferative disease and antiphospholipid syndrome 7
- Use Doppler ultrasound first-line; CT for confirmation
- Rule out underlying cirrhosis when liver tests abnormal or liver dysmorphic
- MR cholangiography for persistent cholestasis or portal biliopathy 7
Anticoagulation in Vascular Liver Disease
Direct oral anticoagulants (DOACs) are emerging as alternatives to traditional anticoagulation 10:
- Recent portal vein thrombosis without cirrhosis: DOACs suggested as alternative to LMWH/warfarin during first 6 months
- Chronic portal vein thrombosis (>6 months): DOACs may be preferred over warfarin for adherence and safety
- Budd-Chiari syndrome: DOACs may be considered when liver function preserved
Contraception considerations: Intrauterine devices, mechanical contraception, and microprogestatives preferred over estrogen-containing oral contraceptives (lower thrombotic risk) 10.
Common Pitfalls
- Relying on HVPG in prehepatic/presinusoidal portal hypertension - it provides no useful data in these conditions 2
- Performing TIPSS in patients with severe liver disease - they cannot tolerate the procedure 9
- Using INR to guide coagulopathy correction - unreliable in liver disease; use thromboelastography 9
- Ignoring hepatic encephalopathy risk assessment before TIPSS - affects one-third of patients 9
- Failing to reduce stent diameter to minimize HE risk when appropriate 9